[{"id":"annals-of-nuclear-medicine","kind":"journal","name":"Annals of Nuclear Medicine","aka":["Ann Nucl Med"],"tldr":"The English-language journal of Japan's nuclear medicine society.","summary":"Annals of Nuclear Medicine is the official English-language journal of the Japanese Society of Nuclear Medicine (id: jsnm), published by Springer, with print ISSN 0914-7187 and electronic ISSN 1864-6433. It is the main route by which Japanese nuclear medicine work - tracer development, dosimetry, clinical PET and SPECT series - reaches an international readership, and the reason Japanese practice is visible in English even though the society's other journal, Kaku Igaku, is Japanese-language only.\n\nFor this corpus it is a monitored feed rather than a congress source: the society does not deposit meeting abstracts with DOIs, so scripts/fetch-pulse.ts reads the journal's recent articles from Crossref by ISSN (no usable RSS feed exists), and the congress harvest leaves it alone.","asOf":"2026-09-22","links":[{"label":"Annals of Nuclear Medicine (Springer): ISSN 0914-7187 print, 1864-6433 electronic","url":"https://link.springer.com/journal/12149"},{"label":"JSNM publications","url":"https://jsnm.org/english/publications/"}],"tags":[],"related":["jsnm","journal-of-nuclear-medicine","ejnmmi"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer (for the Japanese Society of Nuclear Medicine)","url":"https://link.springer.com/journal/12149","issn":"0914-7187","scope":"Nuclear medicine and molecular imaging","access":"hybrid","matchNames":["Annals of Nuclear Medicine","Ann Nucl Med"],"society":"Japanese Society of Nuclear Medicine"},{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","aka":["Ann Oncol","src-annals-oncology"],"tldr":"Annals of Oncology is ESMO's flagship journal, publishing European phase 3 trials, the ESMO Clinical Practice Guidelines and the abstract books for the ESMO Congress.","summary":"Annals of Oncology appears monthly and publishes the ESMO Clinical Practice Guidelines (free to read), ESMO-MCBS benefit scores, trial results often presented at ESMO Congress, translational biomarker studies and the ESMO congress abstract supplements. Published by Elsevier since 2019 (previously Oxford University Press). Hybrid access.","asOf":"2026-09-09","links":[{"label":"ESMO Guidelines","url":"https://www.esmo.org/guidelines"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: ESMO journal: trials, ESMO guidelines, ESMO-MCBS scorecards and congress abstracts. Access: Paywalled; guidelines and abstracts free."],"publisher":"Elsevier","url":"https://www.annalsofoncology.org","issn":"0923-7534","scope":"clinical oncology","access":"hybrid","founded":1990,"impactFactor":{"value":56.7,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Annals of Oncology","Ann Oncol"],"society":"European Society for Medical Oncology"},{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","aka":["Cancer Biotherapy & Radiopharmaceuticals","Cancer Biotherapy and Radiopharmaceuticals","Cancer Biother Radiopharm"],"tldr":"Cancer Biotherapy and Radiopharmaceuticals covers immunotherapy, targeted biological agents and radiolabelled drugs for cancer imaging and treatment, read by nuclear medicine and biotherapy researchers.","summary":"Cancer Biotherapy & Radiopharmaceuticals has been published since 1996 and, according to the NLM catalogue, is issued from 2026 by SAGE Publications in Thousand Oaks, California, following its long run with Mary Ann Liebert; Crossref lists SAGE Publications as the publisher. As its title indicates, its two subjects are cancer biotherapy, meaning biological agents used to treat cancer, and radiopharmaceuticals, meaning radiolabelled compounds used to image and treat it. The NLM record lists it as a United States serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/cbr"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9605408"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publications (formerly Mary Ann Liebert)","url":"https://journals.sagepub.com/home/cbr","issn":"1084-9785","scope":"cancer biotherapy and radiopharmaceuticals","founded":1996,"matchNames":["Cancer Biother Radiopharm","Cancer biotherapy & radiopharmaceuticals","Cancer Biotherapy & Radiopharmaceuticals","Cancer Biotherapy and Radiopharmaceuticals"]},{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","aka":["Cancer imaging : the official publication of the International Cancer Imaging Society","Cancer Imaging"],"tldr":"Cancer Imaging is the open-access journal of the International Cancer Imaging Society, covering CT, MRI, PET and other imaging of cancer. Read by radiologists and nuclear medicine specialists working in oncology.","summary":"Cancer Imaging is the official publication of the International Cancer Imaging Society (ICIS), published by BMC, part of Springer Nature. It is an open access, peer-reviewed journal publishing original articles, reviews and editorials by radiologists specialising in oncology, covering CT, MR, PET, ultrasound, radionuclide and multimodal imaging across tumour sites, including breast, chest, gastrointestinal, hepatobiliary and pancreatic, neuro-oncology, paediatric oncology and theranostics. DOAJ records CC BY and CC0 licences, an article processing charge with waivers, and that authors retain copyright. The journal began in 2000 (originally published by e-med), with the first issue of each early volume carrying the annual ICIS conference; it has been fully open access with BMC since 2014. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://cancerimagingjournal.biomedcentral.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101172931"},{"label":"DOAJ record","url":"https://doaj.org/toc/1470-7330"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://cancerimagingjournal.biomedcentral.com/","issn":"1470-7330","scope":"cancer imaging","access":"open-access","founded":2000,"matchNames":["Cancer Imaging","Cancer imaging"],"society":"International Cancer Imaging Society"},{"id":"chinese-journal-of-nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","aka":["CJNMMI","Zhonghua he yi xue yu fen zi ying xiang za zhi"],"tldr":"China's main nuclear medicine journal. It publishes in Chinese, which is why most of its content is invisible to the usual English-language trackers.","summary":"The Chinese Journal of Nuclear Medicine and Molecular Imaging is sponsored by the Chinese Medical Association and edited by the Jiangsu Institute of Nuclear Medicine, carrying ISSN 2095-2848 and CN 32-1828/R. It was founded in 1981 under an earlier name and has published monthly since 2017. The journal title above is the official English title the publisher itself uses; the journal's contents are in Chinese.\n\nIt is recorded here as a deliberate coverage gap rather than a feed. The journal is not indexed in Crossref (checked 22 September 2026), and a Europe PMC search by journal name returns nothing, so its articles cannot be harvested the way Western journals are. Chinese radiopharmaceutical output is instead tracked through Europe PMC affiliation counts, which returned 6,914 papers with a Chinese affiliation in the year to 22 September 2026, and through worldwide patent filings, where Chinese applicants dominate recent radiopharmaceutical publications.","asOf":"2026-09-22","links":[{"label":"Journal home and masthead (ISSN 2095-2848, CN 32-1828/R)","url":"http://www.zhhyx.com.cn/about.jhtml"},{"label":"Chinese Society of Nuclear Medicine: journal contents","url":"https://chinanm.cma.org.cn/art/2026/4/22/art_1509_60533.html"}],"tags":[],"related":["csnm","china-isotope-radiation"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Chinese Medical Association (edited by the Jiangsu Institute of Nuclear Medicine)","url":"http://www.zhhyx.com.cn/","issn":"2095-2848","scope":"Nuclear medicine and molecular imaging, published in Chinese","access":"subscription","founded":1981,"matchNames":["Chinese Journal of Nuclear Medicine and Molecular Imaging","Zhonghua he yi xue yu fen zi ying xiang za zhi"],"society":"Chinese Society of Nuclear Medicine"},{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","aka":["Clin Cancer Res","CCR","src-clinical-cancer-research"],"tldr":"AACR's clinical journal: phase 1 dose-escalation trials, biomarker studies, pharmacodynamics and the FDA approval summaries written by agency reviewers.","summary":"Clinical Cancer Research appears twice a month and is the main venue for phase 1 trials of new oncology drugs, translational biomarker and pharmacokinetic analyses, and the FDA Oncology Center of Excellence approval summaries that explain the evidence behind each new indication. Hybrid access; free after 12 months.","asOf":"2026-09-09","links":[{"label":"AACR Journals","url":"https://aacrjournals.org"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Phase 1 and 2 trials, biomarker studies and CCR Translations commentaries. Access: Paywalled."],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/clincancerres","issn":"1078-0432","scope":"clinical oncology","access":"hybrid","founded":1995,"impactFactor":{"value":10,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Clinical Cancer Research","Clin Cancer Res","CCR"],"society":"American Association for Cancer Research"},{"id":"clinical-nuclear-medicine","kind":"journal","name":"Clinical Nuclear Medicine","aka":["CNM"],"tldr":"A monthly US medical journal for doctors who use radioactive scans and treatments in everyday patient care.","summary":"Clinical Nuclear Medicine has been published since its first issue in June 1976, making it almost exactly contemporaneous with the first human FDG-PET images acquired that same year. It is a monthly journal from Lippincott Williams & Wilkins (Wolters Kluwer) aimed squarely at clinical practice: diagnostic interpretation, new tracers and imaging techniques, case-based teaching material, and correlation of nuclear medicine findings with other imaging modalities.\n\nIt sits alongside more basic-science-oriented titles such as the Journal of Nuclear Medicine and EJNMMI as one of the main clinical-practice venues in the field, and is frequently cited for case reports and imaging pearls involving PSMA PET, DOTATATE PET and other radiopharmaceutical-based studies that do not fit the format of a full clinical trial report.\n\nAccording to Wolters Kluwer's own journal page, its 2024 Journal Citation Reports impact factor was 9.6.","asOf":"2026-09-22","links":[{"label":"Clinical Nuclear Medicine (LWW journal home)","url":"https://journals.lww.com/nuclearmed/pages/default.aspx"},{"label":"Wolters Kluwer/Ovid: Clinical Nuclear Medicine journal page","url":"https://www.wolterskluwer.com/en/solutions/ovid/clinical-nuclear-medicine-235"},{"label":"PubMed: Historic images in nuclear medicine — the first issue of Clinical Nuclear Medicine (1976)","url":"https://pubmed.ncbi.nlm.nih.gov/24978339/"}],"tags":["journal","nuclear medicine","clinical"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Lippincott Williams & Wilkins (Wolters Kluwer)","url":"https://journals.lww.com/nuclearmed/pages/default.aspx","scope":"Clinical nuclear medicine practice: diagnostic imaging interpretation, new radiopharmaceuticals and tracers, case reports and teaching cases.","access":"subscription","founded":1976,"impactFactor":{"value":9.6,"year":2024,"source":"Wolters Kluwer/Ovid journal page for Clinical Nuclear Medicine"},"matchNames":["Clinical Nuclear Medicine","Clin Nucl Med"]},{"id":"ejnmmi-radiopharmacy-and-chemistry","kind":"journal","name":"EJNMMI Radiopharmacy and Chemistry","aka":["EJNMMI Radiopharm Chem"],"tldr":"A specialist journal, launched in 2015, for the chemistry of making new radioactive imaging and therapy drugs.","summary":"EJNMMI Radiopharmacy and Chemistry launched in late October 2015 as a companion title within the EJNMMI journal family, aimed at chemists, pharmacists, biologists and basic scientists working on new imaging and radionuclide-based therapeutic agents. Its scope covers novel radionuclide production methods, radiochemistry and radiolabelling, new radiopharmaceuticals with first biological evaluation, and molecular imaging agents more broadly (including optical and MRI probes and hybrid probes), as well as best-practice and harmonisation guidance and legislative/regulatory position papers relevant to translating agents to the clinic.\n\nIt received its first Clarivate impact factor in 2023, covering the 2022 JCR release, at 4.6, and is indexed in the Emerging Sources Citation Index under chemistry, medicinal; radiology, nuclear medicine & medical imaging; and chemistry, inorganic & nuclear categories.\n\nAs a Springer Nature/SpringerOpen title, it is fully open access, distinguishing it from its parent journal EJNMMI, which is hybrid.","asOf":"2026-09-22","links":[{"label":"EJNMMI Radiopharmacy and Chemistry home (Springer)","url":"https://link.springer.com/journal/41181"},{"label":"EJNMMI Radiopharmacy and Chemistry aims and scope","url":"https://link.springer.com/journal/41181/aims-and-scope"},{"label":"Editorial launching EJNMMI Radiopharmacy and Chemistry (2016)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5843801/"},{"label":"EJNMMI Radiopharmacy and Chemistry obtains its first impact factor (2023)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10368598/"}],"tags":["journal","radiochemistry","open access"],"related":["ejnmmi"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature (SpringerOpen)","url":"https://link.springer.com/journal/41181","scope":"Radiopharmaceutical chemistry: radionuclide production, radiolabelling and radiosynthesis, new imaging and therapeutic agents, and regulatory/best-practice guidance for translating them to the clinic.","access":"open-access","founded":2015,"impactFactor":{"value":4.6,"year":2022,"source":"EJNMMI Radiopharmacy and Chemistry, PMC editorial announcing its first impact factor (PMC10368598)"},"matchNames":["EJNMMI Radiopharmacy and Chemistry","EJNMMI Radiopharm Chem"]},{"id":"ejnmmi","kind":"journal","name":"European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)","aka":["EJNMMI","European Journal of Nuclear Medicine"],"tldr":"A long-running European medical journal that publishes new research on radioactive scans and radioactive treatments.","summary":"EJNMMI traces back to the European Journal of Nuclear Medicine (EJNM), founded in 1975 and based in Hannover, Germany; it was renamed European Journal of Nuclear Medicine and Molecular Imaging and, according to Springer, was the official journal of the European Association of Nuclear Medicine (EANM) until December 2024. The journal covers clinical and scientific work in functional, metabolic and molecular investigation of disease: diagnostic and therapeutic radiopharmaceuticals, image-guided therapy, physics, dosimetry, radiation biology, radiochemistry and radiopharmacy, plus reviews, short communications and letters (it does not publish case reports).\n\nIn February and July 2025, EANM announced the end of its publishing partnership with Springer Nature and the EJNMMI journal family, and launched two of its own open-access journals with Elsevier — The EANM Journal and EANM Innovation — as the society's new flagship venues. EJNMMI itself continues to publish with Springer Nature independently of that society affiliation; papers citing pre-2025 EANM-endorsed guidelines will generally reference EJNMMI, while post-2025 EANM guidance is increasingly appearing in the new EANM journals instead.\n\nBecause of that transition, records in this graph should check the publication year of any paper before assuming EJNMMI carries current EANM endorsement.","asOf":"2026-09-22","links":[{"label":"EJNMMI home (Springer Nature)","url":"https://link.springer.com/journal/259"},{"label":"EJNMMI aims and scope","url":"https://link.springer.com/journal/259/aims-and-scope"},{"label":"50 years EJNM and EJNMMI (Eur J Nucl Med Mol Imaging, 2023)","url":"https://link.springer.com/article/10.1007/s00259-023-06361-7"},{"label":"EANM: EANM's new own journals (Feb 2025)","url":"https://eanm.org/news/eanms-new-own-journals-feb-2025/"}],"tags":["journal","nuclear medicine"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["eanm"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://link.springer.com/journal/259","scope":"Nuclear medicine and molecular imaging: diagnostic and therapeutic radiopharmaceuticals, image-guided therapy, physics, dosimetry, radiochemistry and radiopharmacy.","access":"hybrid","founded":1975,"matchNames":["European Journal of Nuclear Medicine and Molecular Imaging","Eur J Nucl Med Mol Imaging","EJNMMI"]},{"id":"european-urology","kind":"journal","name":"European Urology","aka":["Eur Urol"],"tldr":"European Urology is the European Association of Urology's journal and the most cited urology title, publishing prostate, bladder and kidney cancer trials, the EAU guidelines and PSMA imaging studies.","summary":"Publishes the EAU guidelines, prostate-cancer screening and active-surveillance cohorts, PSMA PET and radioligand studies, and secondary analyses of the large phase 3 trials in bladder and kidney cancer. Hybrid access via Elsevier; sister titles include European Urology Oncology and European Urology Open Science.","asOf":"2026-09-09","links":[{"label":"EAU Guidelines","url":"https://uroweb.org/guidelines"}],"tags":[],"related":[],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.europeanurology.com","issn":"0302-2838","scope":"urology","access":"hybrid","founded":1975,"impactFactor":{"value":25.2,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["European Urology","Eur Urol"],"society":"European Association of Urology"},{"id":"jama","kind":"journal","name":"JAMA","aka":["Journal of the American Medical Association","JAMA"],"tldr":"JAMA is the American Medical Association's flagship journal. It is strong on cancer screening, prevention, health-services and patient-reported-outcome research, and on the USPSTF recommendations.","summary":"JAMA is a weekly general-medicine journal. In oncology it carries screening and prevention trials, the US Preventive Services Task Force recommendation statements, health-policy and drug-pricing analyses, and landmark care-delivery studies such as Basch's 2017 electronic symptom-monitoring survival result. Hybrid access; research articles are free to read after 12 months.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/JAMA","links":[{"label":"JAMA Network oncology","url":"https://jamanetwork.com/collections/5644/oncology"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Medical Association (JAMA Network)","url":"https://jamanetwork.com/journals/jama","issn":"0098-7484","scope":"general medicine","access":"hybrid","founded":1883,"impactFactor":{"value":63.1,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["JAMA","Journal of the American Medical Association"],"society":"American Medical Association"},{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","aka":["JCO","J Clin Oncol","src-jco"],"tldr":"The Journal of Clinical Oncology is ASCO's flagship journal and the workhorse of clinical oncology, publishing trials, ASCO guidelines, and the abstract supplements for the ASCO Annual Meeting.","summary":"JCO publishes three issues a month, carrying phase 2 and 3 trials across all tumour types, ASCO clinical practice guidelines (for example on immune-related adverse events), health-services and survivorship research, and the annual-meeting abstract supplements that make it the most cited oncology journal by volume. Hybrid access; guidelines are free. Sister titles include JCO Precision Oncology, JCO Oncology Practice and JCO Global Oncology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Journal_of_Clinical_Oncology","links":[{"label":"ASCO guidelines","url":"https://www.asco.org/practice-patients/guidelines"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: ASCO flagship journal: trials, guidelines (including living guidelines) and long-term follow-up of cooperative-group studies. Access: Paywalled; guidelines and many trials free."],"publisher":"American Society of Clinical Oncology","url":"https://ascopubs.org/journal/jco","issn":"0732-183X","scope":"clinical oncology","access":"hybrid","founded":1983,"impactFactor":{"value":42.1,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Journal of Clinical Oncology","JCO","J Clin Oncol","Journal of Clinical Oncology (ASCO Annual Meeting abstract)"],"society":"American Society of Clinical Oncology"},{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","aka":["J Med Imaging Radiat Oncol","JMIRO"],"tldr":"The journal of the Australian and New Zealand college for radiologists and radiation oncologists, covering diagnostic imaging, nuclear medicine and radiotherapy. Read by radiologists and radiation oncologists in Australasia and beyond.","summary":"The Journal of Medical Imaging and Radiation Oncology, also known as JMIRO, is recorded by NLM as the official journal of the Royal Australian and New Zealand College of Radiologists. It is published by Wiley (NLM lists Wiley-Blackwell Publishing Asia) and catalogued from 2008 as an Australian bimonthly, indexed for MEDLINE under Diagnostic Imaging, Neoplasms, Nuclear Medicine and Radiation Oncology. Crossref confirms Wiley as the publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/17549485"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101469340"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/17549485","issn":"1754-9477","scope":"radiology and radiation oncology","founded":2008,"matchNames":["J Med Imaging Radiat Oncol","Journal of medical imaging and radiation oncology","Journal of Medical Imaging and Radiation Oncology","JMIRO"],"society":"Royal Australian and New Zealand College of Radiologists"},{"id":"journal-of-nuclear-cardiology","kind":"journal","name":"Journal of Nuclear Cardiology","aka":["JNC"],"tldr":"The official journal of the American nuclear cardiology society, covering heart scans that use radioactive tracers.","summary":"The Journal of Nuclear Cardiology has published since 1994 and is the official journal of the American Society of Nuclear Cardiology (ASNC); its founding editor was Barry L. Zaret and its current editor-in-chief is Marcelo Di Carli. It covers diagnostic interpretation, imaging equipment and radiopharmaceuticals used in nuclear cardiology, publishing original research, ASNC society guidelines, and discussion of the subspecialty's current and future role alongside competing cardiac imaging modalities.\n\nThe journal was published by Springer for most of its history and moved to Elsevier as publisher in collaboration with ASNC; both the journal's own and Wikipedia's account describe it as still the society's official publication. It is a natural venue for radiopharmaceutical records tied to myocardial perfusion imaging, for example 18F-flurpiridaz PET, and for guideline documents co-authored with SNMMI and ACNM.\n\nAccording to Wikipedia, citing the 2025 Journal Citation Reports (Clarivate, released 2026), its impact factor is 3.0, up from 2.7 in the prior (2024) release.","asOf":"2026-09-22","links":[{"label":"ASNC: Journal of Nuclear Cardiology","url":"https://www.asnc.org/news-publications/journal-of-nuclear-cardiology/"},{"label":"Journal of Nuclear Cardiology — Wikipedia","url":"https://en.wikipedia.org/wiki/Journal_of_Nuclear_Cardiology"}],"tags":["journal","cardiology","nuclear medicine"],"related":["f-18"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.asnc.org/news-publications/journal-of-nuclear-cardiology/","scope":"Nuclear cardiology: myocardial perfusion imaging, cardiac PET and SPECT radiopharmaceuticals, diagnostic interpretation and society guidelines.","access":"subscription","founded":1994,"impactFactor":{"value":3,"year":2025,"source":"Wikipedia, Journal of Nuclear Cardiology, citing 2025 Journal Citation Reports (Clarivate, Web of Science)"},"matchNames":["Journal of Nuclear Cardiology","J Nucl Cardiol"],"society":"American Society of Nuclear Cardiology (ASNC)"},{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","aka":["JNM","J Nucl Med"],"tldr":"The Journal of Nuclear Medicine is the SNMMI's journal and the core venue for PET tracers and radioligand therapy: PSMA and somatostatin imaging, lutetium and actinium dosimetry, and theranostics trials.","summary":"The Journal of Nuclear Medicine appears monthly and publishes first-in-human tracer studies, PSMA PET diagnostic accuracy trials, radioligand-therapy dosimetry and outcomes (lutetium-177 PSMA and DOTATATE, actinium-225), and SNMMI procedure standards. Articles become free to read after a delay; the SNMMI annual meeting abstracts are published as a supplement.","asOf":"2026-09-09","links":[{"label":"SNMMI","url":"https://www.snmmi.org"}],"tags":[],"related":["src-snmmi","lu-177","ac-225"],"indications":[],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Society of Nuclear Medicine and Molecular Imaging","url":"https://jnm.snmjournals.org","issn":"0161-5505","scope":"nuclear medicine","access":"hybrid","founded":1960,"matchNames":["Journal of Nuclear Medicine","JNM","J Nucl Med","The Journal of Nuclear Medicine"],"society":"Society of Nuclear Medicine and Molecular Imaging"},{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","aka":["Nat Med","src-nature-medicine"],"tldr":"Nature Medicine is Nature's clinical journal and now a top venue for early-phase and biomarker-rich cancer trials, medical AI studies and cell-therapy reports.","summary":"Nature Medicine appears monthly and publishes phase 1 and 2 trials with deep translational analysis (MagnetisMM-3 elranatamab in this corpus), circulating tumour DNA and multi-cancer early-detection studies, large medical-AI validations and consensus reporting guidelines for AI in medicine. Hybrid access with a Springer Nature open-access option.","asOf":"2026-09-09","links":[{"label":"Nature Medicine cancer","url":"https://www.nature.com/nm/research-articles?subject=cancer"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Translational medicine including cancer vaccines, AI diagnostics and phase 1 to 3 trials with mechanistic depth. Access: Paywalled; abstracts free; some open access."],"publisher":"Springer Nature","url":"https://www.nature.com/nm/","issn":"1078-8956","scope":"translational medicine","access":"hybrid","founded":1995,"impactFactor":{"value":58.7,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature Medicine","Nat Med"]},{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","aka":["NEJM","N Engl J Med","src-nejm"],"tldr":"NEJM is the most influential medical journal. When a cancer drug trial changes how patients are treated, the paper is usually here, often published the same day it is presented at ASCO, ESMO or ASH.","summary":"Weekly general-medicine journal with the highest bar for randomised evidence and the largest share of practice-changing oncology phase 3 trials (IRIS imatinib, KEYNOTE-189, DESTINY-Breast04, CheckMate 067, ZUMA-1 and dozens more in this corpus). Editorials and correspondence often carry the critical reading of a trial. Paywalled, with abstracts free and many trial papers free six months after publication; requires a data-sharing statement for clinical trials under ICMJE rules.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_New_England_Journal_of_Medicine","links":[{"label":"Hematology/Oncology specialty page","url":"https://www.nejm.org/browse/specialty/hematology-oncology"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: The practice-changing phase 3 trials, most published simultaneously with ASCO, ESMO and ASH presentations. Access: Paywalled; abstracts free; many trial papers free after 6 months."],"publisher":"NEJM Group / Massachusetts Medical Society","url":"https://www.nejm.org","issn":"0028-4793","scope":"general medicine","access":"subscription","founded":1812,"impactFactor":{"value":96.2,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["NEJM","N Engl J Med","New England Journal of Medicine","The New England Journal of Medicine"],"society":"Massachusetts Medical Society"},{"id":"nuclear-medicine-and-biology","kind":"journal","name":"Nuclear Medicine and Biology","aka":["Nucl Med Biol","NMB"],"tldr":"A scientific journal for the chemistry side of radioactive drugs: how they are made, tested in cells and animals, and first tried in patients.","summary":"Nuclear Medicine and Biology began in 1973 as an Elsevier (then Pergamon Press) title and was rebranded in 1985 as Part B of the International Journal of Radiation Applications and Instrumentation before reverting to its current name; it is the official journal of the Society of Radiopharmaceutical Sciences. Its scope is radiopharmaceutical science across the full pipeline: automated and manual radiosynthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy and translational clinical studies of new targeted radiotracers, with editorial guidance that the importance of the biological target should be the primary justification for publication, ahead of chemistry novelty alone.\n\nIt is a natural venue for first-in-human biodistribution and dosimetry papers on new PET/SPECT tracers and for methods papers on radiolabelling chemistry, generator systems and quality control — material that is often too preliminary or too chemistry-focused for the large clinical journals.\n\nElsevier's ScienceDirect Insights page for the journal states an impact factor of 3.0 and a CiteScore of 6.9; third-party trackers place the equivalent Clarivate JCR value in the range of roughly 2.6-3.0 depending on the release year, so the exact figure should be checked against the current JCR release before being quoted precisely.","asOf":"2026-09-22","links":[{"label":"Nuclear Medicine and Biology (ScienceDirect journal home)","url":"https://www.sciencedirect.com/journal/nuclear-medicine-and-biology"},{"label":"Society of Radiopharmaceutical Sciences: Journal page","url":"https://www.srsweb.org/journal"},{"label":"Nuclear Medicine and Biology — history note (60 years of Applied Radiation and Isotopes / Pergamon journals)","url":"https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=922075"}],"tags":["journal","radiochemistry","radiopharmacy"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/nuclear-medicine-and-biology","scope":"Radiopharmaceutical science: synthesis, in vitro/ex vivo evaluation, in vivo biodistribution, radiopharmacology, radiopharmacy and translational clinical studies of radiotracers.","access":"hybrid","founded":1973,"impactFactor":{"value":3,"year":2024,"source":"Elsevier ScienceDirect journal insights page for Nuclear Medicine and Biology; cross-checked against journalsimpactfactors.com (2024 JCR-based value 3.0)"},"matchNames":["Nuclear Medicine and Biology","Nucl Med Biol"],"society":"Society of Radiopharmaceutical Sciences"},{"id":"nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Nuclear Medicine and Molecular Imaging","aka":["Nucl Med Mol Imaging"],"tldr":"The English-language journal of Korea's nuclear medicine society.","summary":"Nuclear Medicine and Molecular Imaging is the official journal of the Korean Society of Nuclear Medicine (id: ksnm), published by Springer with print ISSN 1869-3474 and electronic ISSN 1869-3482. It carries Korean clinical and radiochemistry work in English, which matters here because Korea's radioligand programmes - FutureChem's florastamin and ludotadipep, CellBion's lutetium-177 DGUL - publish domestically well before they appear at Western congresses.\n\nLike its Japanese counterpart it deposits no meeting abstracts, so Nuclide reads it as a literature feed from Crossref by ISSN rather than as a congress source.","asOf":"2026-09-22","links":[{"label":"Nuclear Medicine and Molecular Imaging (Springer): ISSN 1869-3474 print, 1869-3482 electronic","url":"https://link.springer.com/journal/13139"},{"label":"KSNM publication archive","url":"https://www.ksnm.or.kr/eng/pub/search.php"}],"tags":[],"related":["ksnm","cellbion","futurechem","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer (for the Korean Society of Nuclear Medicine)","url":"https://link.springer.com/journal/13139","issn":"1869-3474","scope":"Nuclear medicine and molecular imaging","access":"hybrid","matchNames":["Nuclear Medicine and Molecular Imaging","Nucl Med Mol Imaging"],"society":"Korean Society of Nuclear Medicine"},{"id":"radiology","kind":"journal","name":"Radiology","aka":["Radiology (RSNA)"],"tldr":"Radiology is the RSNA's flagship journal, publishing imaging research including cancer screening performance, AI image analysis and response assessment.","summary":"Radiology appears monthly. In oncology it publishes mammography and lung CT screening performance studies, AI reader studies, contrast and radiation-dose research and imaging-based response and prognosis work. Hybrid access via RSNA; sister titles include Radiology: Artificial Intelligence and Radiology: Imaging Cancer.","asOf":"2026-09-09","links":[{"label":"RSNA","url":"https://www.rsna.org"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Radiological Society of North America","url":"https://pubs.rsna.org/journal/radiology","issn":"0033-8419","scope":"radiology","access":"hybrid","founded":1923,"matchNames":["Radiology"],"society":"Radiological Society of North America"},{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","aka":["Sci Transl Med"],"tldr":"Science Translational Medicine is AAAS's translational journal, publishing the bench-to-bedside cancer papers on liquid biopsy, CAR-T engineering, tumour-immune biology and new imaging agents.","summary":"Science Translational Medicine (Sci Transl Med) is the translational journal of the American Association for the Advancement of Science (AAAS), founded in 2009, appearing weekly and available by subscription with delayed free access. It publishes bench-to-bedside studies with strong mechanistic grounding, including early circulating tumour DNA detection methods, CAR-T design and toxicity work, tumour-immune biology and PET tracer development. Its readers are translational researchers moving discoveries toward the clinic. Within Nuclide it is linked from the biographies of Lecia Sequist, Jeanne Tie, Michel Sadelain, Marcela Maus, Marie-Catherine Vozenin and Constance Lehman, and a reader would use it for the liquid biopsy, CAR-T and imaging papers that precede trials.","asOf":"2026-09-09","links":[{"label":"Science journals","url":"https://www.science.org"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for the Advancement of Science","url":"https://www.science.org/journal/stm","issn":"1946-6234","scope":"translational medicine","founded":2009,"matchNames":["Science Translational Medicine","Sci Transl Med"],"society":"American Association for the Advancement of Science"},{"id":"lancet","kind":"journal","name":"The Lancet","aka":["Lancet"],"tldr":"The Lancet is Britain's leading general medical journal and the other main home of practice-changing cancer trials, with a stronger global-health and policy voice than NEJM.","summary":"The Lancet appears weekly and publishes practice-changing oncology phase 3 trials (CheckMate 649, KEYNOTE-048, CARTITUDE-1, TRANSFORM), the Global Burden of Disease series, and Lancet Commissions that shape cancer policy. Elsevier hybrid model: subscription with an open-access option; abstracts free. Known for editorial campaigning on health inequality and for the HPV-vaccination and cancer-survival population studies that appear in this corpus.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_Lancet","links":[{"label":"Oncology collection","url":"https://www.thelancet.com/clinical/diseases/cancer"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/lancet/home","issn":"0140-6736","scope":"general medicine","access":"hybrid","founded":1823,"impactFactor":{"value":98.4,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["The Lancet","Lancet"]},{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","aka":["Lancet Oncol","src-lancet-oncology"],"tldr":"The Lancet Oncology is the leading specialist cancer journal for clinical trials. It publishes phase 2 and 3 trials, long-term follow-up, quality-of-life analyses and global-oncology policy Commissions.","summary":"The Lancet Oncology appears monthly plus online-first and publishes a large share of randomised oncology trials that do not go to NEJM, with particular strength in radiotherapy, surgery, supportive care and health-system studies (IBIS-I tamoxifen prevention, MASAI AI mammography, GAP70 geriatric assessment in this corpus). Its Commissions and Series drive policy debates on drug pricing, radiotherapy access and cancer in low-income countries. Elsevier hybrid model; abstracts free.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_Lancet_Oncology","links":[{"label":"Lancet Oncology Commissions","url":"https://www.thelancet.com/journals/lanonc/commissions"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Phase 2 and 3 trials, meta-analyses, global oncology policy and the ESMO-aligned commentaries. Access: Paywalled; abstracts free."],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/lanonc/home","issn":"1470-2045","scope":"clinical oncology","access":"hybrid","founded":2000,"impactFactor":{"value":41.6,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Lancet Oncology","The Lancet Oncology","Lancet Oncol"]},{"id":"theranostics-journal","kind":"journal","name":"Theranostics","aka":[],"tldr":"A fully free-to-read journal that publishes research combining diagnosis and treatment, including radioactive drugs.","summary":"Theranostics is a biweekly, fully open-access journal established in 2011 and published by Ivyspring International Publisher. It covers in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, systems biology and translational and personalised medicine — a broad remit that in practice makes it one of the most frequently cited venues for new PET and SPECT radiotracers, radioligand therapy chemistry, and nanomedicine-based theranostic agents.\n\nArticles are published under a CC BY-NC licence and are immediately free to read, with no subscription barrier; the journal states full compliance with NIH public access requirements. It is indexed in Web of Science (Science Citation Index Expanded), MEDLINE/PubMed and Scopus.\n\nAccording to the journal's own indexing page, its Journal Citation Reports impact factor was 12.4 for the 2024 JCR release, up from 11.556 in the 2022 release; third-party trackers report further increases in more recent JCR cycles, which readers should verify against Clarivate directly given how fast the metric has moved.","asOf":"2026-09-22","links":[{"label":"Theranostics home","url":"https://www.thno.org/"},{"label":"Theranostics: Index and ranking (impact factor history)","url":"https://www.thno.org/indexrank"}],"tags":["journal","open access","theranostics"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Ivyspring International Publisher","url":"https://www.thno.org/","scope":"Theranostics: molecular imaging, molecular therapeutics, image-guided therapy, biosensors, nanomedicine and translational/personalised medicine.","access":"open-access","founded":2011,"impactFactor":{"value":12.4,"year":2024,"source":"Theranostics journal, Index and ranking page (thno.org/indexrank), citing the 2024 Journal Citation Reports release"},"matchNames":["Theranostics"]}]